Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

Pembrolizumab Continues to Show Modest Clinical Activity in Advanced Ovarian Cancer

June 23rd 2020

Pembrolizumab demonstrated modest clinical activity in patients with advanced recurrent ovarian cancer.

Dr. Slomovitz on Sequencing Strategies for Endometrial Cancer

June 16th 2020

Brian M. Slomovitz, MD, discusses sequencing strategies for endometrial cancer.

Dr. Matulonis on Final Data From KEYNOTE-100 in Recurrent Ovarian Cancer

June 10th 2020

Ursula A. Matulonis, MD, discusses final data from the phase 2 KEYNOTE-100 trial with pembrolizumab (Keytruda) in advanced recurrent ovarian cancer.

Nivolumab/Ipilimumab Induction Therapy Boosts Responses and Prolongs PFS in Epithelial Ovarian Cancer

June 10th 2020

The combination of nivolumab plus ipilimumab was found to induce a superior response rate and longer progression-free survival compared with nivolumab alone in patients with persistent or recurrent epithelial ovarian cancer.

Dr. Zakashansky on Repeat Exposure to PARP Inhibitors in Patients With Ovarian Cancer

June 8th 2020

Konstantin Zakashansky, MD, gynecologic oncologist and associate professor of Obstetrics, Gynecology and Reproductive Science at Mount Sinai Health System, discusses repeat exposure to PARP inhibition in patients with platinum-sensitive, relapsed ovarian cancer.

Dr. Liu on Phase 2 Study Results of Adavosertib in Recurrent Uterine Serous Carcinoma

May 30th 2020

Joyce F. Liu, MD, MPH, discusses findings from a phase 2 study with the Wee1 inhibitor adavosertib in patients with recurrent uterine serous carcinoma.

Avelumab Controls hCG Levels Lead to Remissions in Gestational Trophoblastic Tumors

May 29th 2020

Gestational trophoblastic tumors (GTTs) that resist chemotherapy can be treated with frontline avelumab, making avelumab the first immunotherapy to show efficacy in treating patients with GTT, according to findings from a cohort of the ongoing phase 2 TROPHIMMUN trial.

Maintenance Niraparib Boosts PFS in Phase 3 Study of Chinese Patients With Ovarian Cancer

May 29th 2020

Maintenance niraparib improved progression-free survival in Chinese patients with recurrent ovarian cancer who were in a complete or partial response to platinum-based chemotherapy, meeting the primary end point of the phase 3 NORA study.

Level 1 Evidence Needed to Drive Optimal Sequencing Strategies in Endometrial Cancer

May 20th 2020

Brian M. Slomovitz, MD, explaines the need to determine optimal sequencing strategies in endometrial cancer.

Level 1 Evidence Needed to Drive Optimal Sequencing Strategies in Endometrial Cancer

May 20th 2020

Brian M. Slomovitz, MD, explaines the need to determine optimal sequencing strategies in endometrial cancer.

Dr. Westin on Novel Targets in Endometrial Cancer

May 12th 2020

Shannon N. Westin, MD, MPH, discusses novel targets in endometrial cancer.

Herzog Highlights Approval of Olaparib/Bevacizumab as Frontline Maintenance in HRD+ Ovarian Cancer

May 9th 2020

Thomas Herzog, MD, discusses the FDA approval of olaparib plus bevacizumab for the frontline maintenance treatment of patients with homologous recombination deficiency–positive ovarian cancer.

Antibody-Drug Conjugate STRO-002 Active in Advanced Ovarian Cancer

May 9th 2020

The anti–folate receptor alpha antibody-drug conjugate STRO-002 showed early clinical promise in patients with advanced ovarian cancer.

Vaccine BVAC-C Shows Early Promise in Cervical Cancer

May 8th 2020

The vaccine BVAC-C demonstrated durable antitumor activity in patients recurrent cervical cancer.

Future Looks Bright in Endometrial Cancer, With Exciting Emerging Agents and Targets

May 6th 2020

Shannon N. Westin, MD, MPH, FACOG, discusses future directions in endometrial cancer.

Salani Sheds Light on the Rising Role of Biomarkers in Cervical Cancer

May 5th 2020

Ritu Salani, MD, discusses the evolving role of biomarker development and testing in cervical cancer.

IMRT Improves Patient-Reported Outcomes in Cervical and Endometrial Cancer

May 4th 2020

A reduction in patient-reported symptomatic adverse events was observed with intensity-modulated radiotherapy compared with standard radiotherapy in patients with cervical or endometrial cancer, whereas no difference was observed with regard to clinician-reported AEs.

Dr. Coleman on Recent Advancements Made in Cervical Cancer Treatment

May 2nd 2020

Robert L. Coleman, MD, FACOG, FACS, discusses recent advancements made in the cervical cancer space.

Dr. Naumann on Data With STRO-002 in Platinum-Resistant/Refractory Ovarian Cancer

May 2nd 2020

R. Wendel Naumann, MD, gynecologic oncologist, Levine Cancer Institute, Carolinas HealthCare System/Atrium Health, discusses data with STRO-002 in patients with platinum-resistant/refractory ovarian cancer.

FDA Approves Niraparib for Frontline Maintenance in Ovarian Cancer

April 29th 2020

The FDA has approved niraparib for use as a frontline maintenance treatment for women with advanced ovarian cancer who responded to platinum-based chemotherapy.